3-Bromo-5-nitropyridine

We are 3-Bromo-5-nitropyridine CAS:15862-30-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  3-Bromo-5-nitropyridine
CAS.NO:15862-30-3
Synonyms:    3-Bromo-5-nitropyridine
3-Bromo-5-Nitropyridine
3-bromanyl-5-nitro-pyridine
3-Brom-5-nitropyridin
Pyridine,3-bromo-5-nitro
 
Molecular Formula:C5H3BrN2O2
Molecular Weight:202.99400
 
Physical and Chemical Properties:
Density:1.833g/cm3
Boiling point:251.6ºC at 760mmHg
Melting point:/
Flash point:106ºC
Index of Refraction:1.614
 
Specification:
Appearance:White Crystalline Powder
Purity:≥99.0%
 
Packing:25kg/drum, can also be packaged according to customer requirements
Storage:Preserve in well-closed, light-resistant and airtight containers
Application: Pesticide intermediates, dye intermediates, flavor and fragrance intermediates, pharmaceutical intermediates

3-Bromo-5-nitropyridine


Related News: Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important.(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate CAS:156311-83-0 An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.2-Chloro-3-nitro-5-(trifluoromethyl)pyridine An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethanamine CAS:78441-62-0 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
2-acetyl-5-methylfuran View Details
2-Bromoethyl ethyl ether View Details
(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate View Details
Methyltriethoxysilane manufacturer 5-(3-methylbut-2-enoxy)-5-oxo-2-[2-(phenylmethoxycarbonylamino)-1,3-thiazol-4-yl]pent-2-enoic acid manufacturer Methyl (2E)-3-[3-(trifluoromethyl)phenyl]acrylate manufacturer Bisoctrizole manufacturer Allylamine manufacturer